Clearside Biomedical, headquartered in Alpharetta, Georgia, specializes in therapies delivered to the eye via the suprachoroidal space and has developed the approved product XIPERE. The company’s lead program, CLS-AX, is in Phase 2b clinical testing for wet AMD.